Dr. Boisen’s work has focused primarily on women with gynecologic malgnancies and particularly on women with ovarian cancer. Her laboratory work has involved collaboration with Dr. Steffi Oesterreich in characterizing signatures of estrogen receptor signaling in both high grade serous and endometriosis-associated ovarian cancers. Clinically, Dr. Boisen has an interest in evaluating therapeutic strategies for ovarian cancer and has published in the area of intraperitoneal chemotherapy and HIPEC. Currently she is working with several other division members looking at the outcomes of patients treated with neoadjuvant chemotherapy. Dr. Boisen is also interested improving post-operative outcomes and is working in conjunction with others in the division and within the healthcare system to implement an enhanced surgical recovery pathway.
Education & Training
- Fellowship, University of Pittsburgh Medical School, Pittsburgh, PA
- Residency, University of Pittsburgh Medical School, Pittsburgh, PA
- MD, University of Wisconsin School of Medicine, Madison, WI
- Boisen MM, Lesnock JL, Richard SD, Beriwal S, Kelley JL, Zorn, KK, Edwards RP. Second-line Intraperitoneal Platinum-based Therapy Leads to an Increase in Second Line Progression-free Survival for Epithelial Ovarian Cancer. Int J Gynecol Cancer. 2016 May;26(4):626-31.
- Delgado E, Boisen MM, Laskey R, Chen R, Song C, Sallit J, Yochum ZA, Andersen CL, Sikora MJ, Wagner J, Safe S, Elishaev E, Lee A, Edwards RP, Haluska P, Oesterreich S. High expression of orphan nulclear receptor NR4A1 in a subset of ovarian tumors with worse clinical outcome. Gynecol Oncol. 2016 May; 141(2):348-56.
- Boisen MM, Richard SD, Holtzman MP, Edwards RP, Kelley JL, Choudry MH, Bartlett D, Huang M. Hyperthermic intraperitoneal chemotherapy for epithelial ovarian cancers: is there a role? J Gastrointest Oncol. 2016 Feb;7(1):10-7.
- Boisen MM, Andersen CL, Sreekumar S, Stern AM, Oesterreich S. Treating gynecologic malignancies with selective estrogen receptor downregulators (SERDs): promise and challenges. Mol Cell Endocrinol. 2015;418:322-33. PMID 26276546.